NIH Requires New Biosketch Format for Due Dates on or After January 25, 2015
The National Institutes of Health (NIH) recently announced that a new biosketch format will be required for all applications submitted for FY2016 funding, which begins with due dates of January 25, 2015.
The NIH has been piloting a planned modification of the biosketch since June 2012. The new format increases the page limit from 4 to 5 pages and increases the number of peer-reviewed publications from 15 to 20.
The new format allows investigators to include a link to a complete listing of their publications in SciENcv or My Bibliography. Within the next few weeks, the NIH will update SciENcv to accommodate the new biosketch format.
Visit the NIH website under the heading “Additional Format Pages” to obtain templates for the new biosketch format: http://grants.nih.gov/grants/funding/424/index.htm.
Local Assistance Available with New Biosketch Formatting
Contact Kathy Blazer, Interim Director, Cleveland Health Sciences Library, (216-368-1361 or firstname.lastname@example.org) if interested in having Kathy conduct a departmental information session, or to answer individual questions.
Review the Health Sciences Library's slide presentation at: http://www.case.edu/chsl/library/NIHBiosketch.pptx.
Ohio Third Frontier (OTF), Ohio Development Services Agency
The goal of the Ohio Third Frontier Technology Validation and Start-Up Fund (TVSF) is to increase economic growth in Ohio through start-up companies that commercialize technologies developed by Ohio institutions of higher education and other Ohio not-for-profit research institutions. Two separate mechanisms have been set up to achieve these goals:
Phase 1 –Technology Validation The specific objectives of this phase are as follows:
• To generate the proof needed to move technology to the point that it is either ready to be licensed by an Ohio start-up company or otherwise deemed unfeasible for commercialization.
• To fund validation activities, such as prototyping, demonstrations, and assessment of critical failure points in subsequent development, scale-up, and commercialization.
Phase 2 – Start-Up Funds The specific objectives of this phase are as follows:
• To support Ohio start-up companies that have licensed technology developed at Ohio research institutions during the critical early life of the company, and accelerate the time to market of this technology.
• To generate the proof needed to either commercialize the technology or move the technology to the point where additional funds needed for commercialization can be raised.
• To fund activities in order to generate the needed proof.
The TVSF will support technology that falls within the following areas: Advanced Materials related to advanced polymers, ceramics, composites, carbon fibers and nanotubes and specialty metals and alloys; Aeropropulsion Power Management; Agribusiness and Food Processing; Fuel Cells and Energy Storage; Medical Technology related to imaging, surgical instruments/equipment, implant devices, and regenerative medicine; Software Applications for business and healthcare; Sensing and Automation Technologies; Situational Awareness and Surveillance Systems; Solar Photovoltaics; and Shale.
Potential CWRU Applicants - Contact:
Michael Haag, MS, MBA, Executive Director, Technology Management, 216-368-6106 or email@example.com.
For more information on the TVSF visit the Ohio Third Frontier website.
NIH Center for Accelerated Innovation at Cleveland Clinic (NCAI-CC)
The NIH Center for Accelerated Innovation at Cleveland Clinic (NCAI-CC)
Announces the Request for Applications (RFA) for the third funding cycle.
Funding is available for promising emerging technologies directed towards diagnosis, treatment or management of cardiovascular, pulmonary, blood or sleep-related disorders. NCAI-CC is seeking projects such as therapeutics (e.g. drugs, biologics), preventatives, diagnostics, devices, tools, etc., in order to facilitate their translation to commercialized products that improve patient care and enhance health. The NCAI-CC will provide funding and project assistance to advance the development of high priority early-stage technologies within the mission areas of the NHLBI (cardiovascular, lung, blood and sleep disorders). Expert assistance will be provided in areas required for early technology development, including commercial opportunity assessment, intellectual property, clinical and regulatory, reimbursement, business, legal and project management.
Eligibility: Investigators from the Cleveland Clinic, Case Western Reserve University, The Ohio State University,Cincinnati Children’s Hospital, and University of Cincinnati
Letter of Intent Deadline: February 10, 2015
For more information visit the NCAI-CC website.
National Multiple Sclerosis Society
The Barancik Prize for Innovation in Multiple Sclerosis Research recognizes an exceptional scientist or a team of scientists whose work in MS research has demonstrated outstanding innovation and originality.
The prize is administered by the National Multiple Sclerosis Society. A selection committee comprised of leaders in science, medicine, and MS advocacy will review nominees. The committee will evaluate:
• Exceptional innovation and originality in scientific research relevant to MS
• Impact and potential of the research to lead to pathways for the treatment and cure for MS
• Scientific accomplishments that merit recognition as a future leader in MS research
For more information and guidelines , visit the Society’s website.
Foundation Fighting Blindness and Harrington Discovery Institute
Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.
• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
• Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.
Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.
For more information about Foundation Fighting Blindness visit the Fighting Blindness website.
If you have news or information that you wish to have included in this
update, please send it via e-mail to Tracy Wilson-Holden at
firstname.lastname@example.org no later than
5 pm on the Monday of the week that the update is to be distributed. If you
know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe
to Case Research News, email your request to Tora Williams at
Please note: At the time of this transmission, all links functioned.
However, Case Research News cannot guarantee that the information will not move or be